Prestige Consumer Healthcare In (PBH) concentration risks

The company's disclosed concentration risks span both the supply side and the customer side, with each individual exposure falling in the low-share band. On supply, a privately owned pharmaceutical manufacturer accounted for approximately 21% of gross revenues — a low-share dependency that nonetheless represents a meaningful production relationship where any disruption to manufacturing capacity, regulatory standing, or the contractual arrangement could affect product availability across a portion of the portfolio. On the customer side, two major retail channels are individually disclosed. Walmart accounted for approximately 20% of gross revenues, a low-share dependency on a single retail partner whose shelf-space and promotional decisions directly influence sell-through. Amazon accounted for approximately 15% of gross revenues — also a low-share dependency, and one tied to a platform whose algorithmic ranking, fulfillment policies, and own-brand competition can shift the effective economics of any consumer health brand at short notice. Taken together, the three exposures are each contained individually, but they are partially correlated: a shift in consumer purchasing away from mass retail and toward specialty channels could affect both the Walmart and Amazon relationships simultaneously. The supply-side concentration compounds this by limiting the flexibility to substitute products if the manufacturing relationship were disrupted. The profile warrants monitoring at the contract-renewal and channel-mix level rather than as an acute single-event risk.

For the engine’s reasoning on PBH’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.

Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.